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Introduction {#j_raon-2015-0009_s_001}
============

Uveal melanoma is the most common primary malignancy of the eye.[@j_raon-2015-0009_ref_001] Approximately 90% of all uveal melanoma develop in the choroid, 7% in the ciliary body and 3% in the iris.[@j_raon-2015-0009_ref_002] The disease is more common in older age, with the highest incidence at about 60 years of age.[@j_raon-2015-0009_ref_001],[@j_raon-2015-0009_ref_002] For the period 1983--1994, the incidence of uveal melanoma in 16 European countries was analysed by the European Cancer Registry (EUROCARE).[@j_raon-2015-0009_ref_003] The incidence in Europe was found ascend from South to North, being 2/million inhabitants in Spain and southern Italy and more than 8/million in Denmark and Norway. In Slovenia, the incidence of choroid melanoma between 1983-2009 was stable, at 7.8 cases/million for men and 7.4/million for women.[@j_raon-2015-0009_ref_004]

In the majority of patients, the biopsy of tumour is not indicated because the accuracy of clinical diagnosis is reaching 99%.[@j_raon-2015-0009_ref_005] However, there is no agreement about the optimal therapy.[@j_raon-2015-0009_ref_006]--[@j_raon-2015-0009_ref_0010] Until development of eye conserving therapies in 1960's, for more than 100 years, enucleation was the only mode of treatment. The first among eye conserving approaches was the plaque brachytherapy[@j_raon-2015-0009_ref_009],[@j_raon-2015-0009_ref_0011]--[@j_raon-2015-0009_ref_0014], followed by proton beam[@j_raon-2015-0009_ref_0015]--[@j_raon-2015-0009_ref_0017] and helium ion radiotherapy[@j_raon-2015-0009_ref_0018]--[@j_raon-2015-0009_ref_0020], stereotactic radiotherapy, transscleral or transretinal local resection[@j_raon-2015-0009_ref_0010],[@j_raon-2015-0009_ref_0021],[@j_raon-2015-0009_ref_0022], and phototherapy brachytherapy[@j_raon-2015-0009_ref_0023], several types of radioactive plaques with photon emitting isotopes were used, including cobalt-60, iodine-125, and iridium-192. Beta emitting plaques with ruthenium (106Ru/106Ro), however, were introduced in 1964 by Lommatzsch.[@j_raon-2015-0009_ref_0024]--[@j_raon-2015-0009_ref_0026]

In Slovenia, treatment of choroidal melanoma by brachytherapy with ruthenium plaques using the Lommatzsch method was introduced in 1985 by the Eye Clinic at the University Clinical Centre Ljubljana in collaboration with the Institute of Oncology Ljubljana.[@j_raon-2015-0009_ref_0027],[@j_raon-2015-0009_ref_0028] Before that time, the only available treatment was enucleation of the diseased eye. The aim of this retrospective study was to evaluate these two modalities in the treatment of choroidal melanoma in Slovenia during the period from 1986 to 2008 and to determinate the prognostic factors of survival for choroidal melanoma patients in Slovenia.

Patients and methods {#j_raon-2015-0009_s_002}
====================

Patients {#j_raon-2015-0009_s_002_s_001}
--------

The database of the Cancer Registry of Slovenia was used for identification of patients with the diagnosis of choroidal melanoma in Slovenia in the years 1986--2008.[@j_raon-2015-0009_ref_004] The medical records of identified patients from the Eye Hospital of the University Clinical Centre Ljubljana and from the Department of Ophthalmology of the University Medical Centre Maribor were reviewed for relevant information on clinical characteristics, treatment and outcome. The diagnosis of choroidal melanoma was based on clinical features and full ophthalmologic examination, indirect ophthalmoscopy, fundus photography, ultrasonography and fluorescein angiography. At the time of diagnosis, the patients were evaluated by chest radiography, lymph gland and liver ultrasonography[@j_raon-2015-0009_ref_0029] and routine blood tests. Genetic testing was not done because it was not available at the time of the study.

The study was approved by the institutional review board and was carried out according the Helsinki Declaration.

Treatment {#j_raon-2015-0009_s_002_s_002}
---------

Applicators manufactured by Bebig (Eckert&Ziegler BEBIG Gmbh, Berlin; later Amersham, GB) were used. The applicators were concave, shell-shaped, with Ru-106/Ro-106 isotope covering the concave surface as a thin, insoluble film and emitting beta rays with the energy of 3.54 MeV and half-life of 373 days. The tumours were localized by transillumination and indirect ophthalmoscopy, and the applicators were sutured to the sclera. The dose at the tumour apex was aimed to be about 120 Gy. The applicator was removed after expiration of appropriate time.

Treatment was selected according to the tumour size: patients with tumours ≤ 16 mm in diameter and ≤ 7.2 mm thick, with useful vision preserved, were treated by brachytherapy, patients with larger tumours had enucleation. The enucleation was performed in general anaesthesia.

First follow-up visits took place one month after the procedure, in 3-month intervals during the first year and once a year thereafter. At each follow up visit, patients underwent ophthalmologic examinations with indirect ophthalmoscopy, fundus photography and ultrasonography.

Statistical methods {#j_raon-2015-0009_s_002_s_003}
-------------------

For comparative analyses, the Fisher exact test for two proportions as well as t-test and Mann-Whitney test for data of two independent groups were used. Survival estimates were carried out using the Kaplan-Meier method and reported at 5 and 10 years follow up. The difference between the survival curves was evaluated by means of a log-rank comparison. Multivariate survival analysis for study of an independent effect of various parameters that appeared statistically significant on univariate analysis to treatment outcome and survival was performed according to Cox's proportional hazard models with backward stepwise selection. The end points of survival analysis were locoregional control (LRC, persistent disease or locoregional recurrence considered as an event), disease-free survival (DFS, appearance of loco-regional recurrence or systemic metastases considered as event), disease-specific survival (DSS, melanoma related death considered as event) and overall survival (OS, death from any cause considered as event) which were measured from the first day of therapy. These statistical analyses were performed by using SPSS version 18.0 (SPSS Inc., Chicago, IL) and nonlinear regression Gaussian curve fitting was performed by GraphPad Prism version 5. All tests were two-sided and a P-value of 0.05 was considered statistically significant.

Results {#j_raon-2015-0009_s_003}
=======

Clinical records of 288 patients with choroidal melanoma treated from January 1986 to December 2008 at the Eye Hospital of the University Clinical Centre Ljubljana and from the Department of Ophthalmology of the University Medical Centre Maribor were reviewed. The follow-up close-out date was December 31, 2013. Median follow-up of all patients was 15 years (range, 4--27 years). In December 2013, 130 patients were alive. The cause of death was melanoma in 107 patients and 51 patients died of melanoma unrelated disease; 20 among them died of other malignant diseases. The characteristics of patients and tumours are shown in [Table 1](#j_raon-2015-0009_tab_001){ref-type="table"}.

###### 

The characteristics of patients and tumours by treatment modality

                                       Treatment    
  -------------------- --------------- ------------ -----
  **All patients**     130             161          291
  **Excluded**         3 palliations   \-           3
  **Treated**          127             161          288
  **Gender**                                        
   Man                 58              84           142
   Women               69              77           146
  **Age (median)**                                  
   Men                 58 (29-74)      58 (19-86)   
   Women               60 (22-89)      61 (23-92)   
  **T-stage (AJCC)**                                
   1                   38                           
   2                   69                           
   3                   8                            
   No data             12                           
  **Thickness**                                     
   \< 3 mm             11                           
   3.1-5.0 mm          64                           
   5.1-7.2 mm          49                           
   \> 7.8 mm           3                            
   No data             0                            
  **Basal diameter**                                
   ≤ 10 mm             52                           
   10,1-12,0 mm        38                           
   \> 12 mm            25                           
   No data             12                           
  **Histology**        161                          
   Spindle cell        33                           
   Epithelioid         38                           
   Mixed               23                           
   No data             37                           

AJCC = American Joint Committee on Cancer

Survival {#j_raon-2015-0009_s_003_s_001}
--------

In univariate analysis of all patients, the LRC and DFS were better in enucleation than in brachytherapy group and better in females than in males. Patients \< 60 years had better DFS, DSS and OS than older patients. In brachytherapy group, females had statistically better LRC and DFS than males; younger patients had better DSS and OS than older patients. Tumour thickness \< 6 mm was associated with better LRC and DFS than thicker tumours, while the base diameter \< 11 mm was a good prognostic sign for LRC; DFS, DSS and OS. The treatment time influenced LRC and DFS, while the dose-rate had no influence of the outcome of the treatment. In the enucleation group, age and histology influenced DFS, DSS and OS, while sex had no effect on survival. The detailed data of survival are presented in Tables 2--4.

In multivariate analysis for all patients, gender was independent prognostic factor for LRC, while first treatment and age were independent prognostic factors for DFS, DSS and OS. In the brachytherapy group, gender was independent prognostic factors for LRC; treatment time for LRC and DFS; base diameter for DFS and OS. The age was independent prognostic factor for DFS and OS. In enucleation group, age and histology were independent prognostic factors for DFS and DSS, while on OS influenced only age ([Table 5](#j_raon-2015-0009_tab_005){ref-type="table"}).

Second treatment {#j_raon-2015-0009_s_003_s_002}
----------------

In 30 patients treated by brachytherapy, a local recurrence of the tumour occurred. The second application of ruthenium plaque was performed in 13 of these patients, and in 17 patients had enucleation: 12 patients - because of extent of the recurrent tumour and 5 patients - because of the treatment-related side effects (glaucoma, cataract). The eyes were enucleated from 7 months to 18 years (median 24 months) after the first brachytherapy ([Figure 1](#j_raon-2015-0009_fig_001){ref-type="fig"}).

![Overall survival of patients treated by brachytherapy after treatment of recurrence.](j_raon-2015-0009_fig_001){#j_raon-2015-0009_fig_001}

###### 

Univariate analysis of survival: all patients (N = 288)

                n     LRC (%)   DFS (%)   DSS (%)   OS (%)                                                              
  ------------- ----- --------- --------- --------- -------- -------- ------- ------- -------- ------- ------- -------- -------
                      5 yrs     10 yrs    p         5 yrs    10 yrs   p       5 yrs   10 yrs   p       5 yrs   10 yrs   p
  All           288   90        88        \-        65       50       \-      76      58               68      46       \-
  Ruthenium     127   78        75                  71       60               92      79               87      68       
                                          0.000                       0.014                    0.000                    0.000
  Enucleation   161   100       100                 60       42               64      42               54      31       
  Men           142   85        82                  61       51               74      61               66      47       
                                          0.026                       0.673                    0.647                    0.952
  Women         146   95        93                  69       49               78      55               70      46       
  \< 60 years   150   89        86                  74       58               86      68               84      64       
                                          0.648                       0.002                    0.000                    0.000
  ≥ 60 years    138   90        90                  56       40               65      47               52      28       

DFS = disease free survival; DSS = disease specific survival; LRC = loco-regional control; n = number of patients; OS = overall survival; yrs = years

###### 

Univariate analysis of survival: patients treated by brachytherapy (N = 127)

                                LRC (%)   DFS (%)   DSS (%)   OS (%)                                                              
  ------------------------ ---- --------- --------- --------- -------- -------- ------- ------- -------- ------- ------- -------- -------
                           n    5 yrs     10 yrs    p         5 yrs    10 yrs   p       5 yrs   10 yrs   p       5 yrs   10 yrs   p
  Men                      58   66        60                  60       49               90      76               87      67       
                                                    0.003                       0.039                    0.703                    0.859
  Women                    69   89        87                  81       69               93      81               88      70       
  \< 60 years              68   76        71                  76       66               98      89               98      83       
                                                    0.305                       0.156                    0.002                    0.000
  ≥ 60 years               59   80        80                  65       51               84      65               75      52       
  T-stage                                                                                                                         
   1                       38   79        79                  73       67               97      84               94      71       
   2                       69   79        74        0.451     72       57       0.354   90      75       0.378   86      72       0.508
   3                       8    60        40                  45       45               86      86               0       50       
  Tumour thickness                                                                                                                
   2-5.9 mm                97   83        82        0.003     74       66       0.021   92      79       0.489   86      68       0.724
   6-.2 mm                 29   64        54        64        39       96       80      96      70                                
  Base                                                                                                                            
   \< 11 mm                61   83        83        0.043              80       0.002   96      84       0.024   96      77       0.002
   ≥ 11 mm                 54   70        64        60        45       87       72      78      64                                
  Dose rate Top (Gy/h)                                                                                                            
   ≥ 108 Gy                53   81        78        0.302     74       66       0.099   95      84       0.280   87      72       0.690
   \< 108 Gy               52   74        68        68        46       89       72      87      62                                
  Dose- rate base (Gy/h)                                                                                                          
   ≥ 532                   53   82        74        0.708     74       57       0.804   95      81       0.665   87      69       0.862
   \< 532                  52   74        71        68        55       89       75      87      65                                
  Treatment time                                                                                                                  
   ≤ 96 hours              52   87        84        0.015     80       72       0.004   95      84       0.400   89      74       0.565
   \> 96 hours             53   68        62        62        40       89       71      85      60                                

DFS = disease free survival; DSS = disease specific survival; LRC = loco-regional control; n = number of patients; OS = overall survival; yrs = years

Distant metastases {#j_raon-2015-0009_s_003_s_003}
------------------

Twenty-five of 127 patients treated by brachytherapy and 86 of 161 those treated by enucleation developed systemic metastases. Seventy per cent of all metastases were localized in the liver. The actuarial rates of metastases by treatment modality are depicted in [Figure 2](#j_raon-2015-0009_fig_002){ref-type="fig"}. At 5 and 10 years, the incidences were 39% and 57%, respectively, for enucleated patients, and 11% and 21%, respectively, for irradiated patients (P \< 0.001).

![Incidence of distant metastases according to the type of treatment.](j_raon-2015-0009_fig_002){#j_raon-2015-0009_fig_002}

In patients treated by brachytherapy, half of the metastases developed in 5 years, and in those treated by enucleation in 2.6 years.

Annual melanoma specific mortality rate {#j_raon-2015-0009_s_003_s_004}
---------------------------------------

The mortality of patients was increased in the first few years after treatment and then slowly returned to pre-treatment values. Melanoma specific mortality rate is displayed in [Figure 3](#j_raon-2015-0009_fig_003){ref-type="fig"}.

![Percentage of annual post-treatment melanoma specific mortality according to the type of treatment. ^\*^There was no peak in ruthenium treated patients \< 60 years.](j_raon-2015-0009_fig_003){#j_raon-2015-0009_fig_003}

The peak percentage of annual melanoma specific mortality after treatment was achieved at 3.6 years for patients older than 60 years treated by enucleation and at approximately 6 years for younger enucleated patients and for all patients treated with brachytherapy. The irradiated patients below 60 years contributed little to the peak because of low mortality rate.

No patient from brachytherapy group aged below 40 years died of melanoma. In brachytherapy treated patients the mortality began to increase after the age of 40 and reached 40 % in 70--80 year's age group. In patients treated by enucleation, the mortality started to increase one decade earlier: the rise started with about 40% and reached about 70 % in patient's 80--90 years of age ([Figure 4](#j_raon-2015-0009_fig_004){ref-type="fig"}).

![Linear regression analysis of melanoma related mortality per age decades, according to the type of treatment. Points represent percent mortality rate for the elapsed decade. No patient less than 40 years who was treated with Ru-106 died of melanoma.](j_raon-2015-0009_fig_004){#j_raon-2015-0009_fig_004}

Complications {#j_raon-2015-0009_s_003_s_005}
-------------

Because of retrospective character of the study, acute complications were not systematically recorded. For chronic complications patients were reviewed annually. Post-radiation retinopathy started to appear after two years and was documented in 18 patients (12 mild, 6 severe), neovascular glaucoma in 5 patients and cataract in 6 patients. None of the patients had optic neuropathy.

Vision after treatment {#j_raon-2015-0009_s_003_s_006}
----------------------

After brachytherapy, the eye was retained in all patients and the vision was assessed in 112 patients. Compared to pre-treatment status, 22 (19.6%) patients had better visual acuity; in 12 (10.7%) patients the vision was unchanged while in 78 (69.6%) patients the acuity of vision was worse. The majority of brachyradiotherapy patients retained vision which was better than counting fingers.

Discussion {#j_raon-2015-0009_s_004}
==========

Our retrospective study reports results of the treatment of patients with choroidal melanoma in Slovenia from 1986 to 2008. In our study, the overall and specific mortality rate in patients treated by enucleation was higher mainly because larger tumours were selected for enucleation as compared to those treated by brachytherapy. Brachytherapy could be used only for selected tumours, depending on their size, location and shape of applicators, for which a satisfactory dose distribution of dose can be achieved. Because no data about the dimensions of the enucleated tumours was available, comparison of results between the two treatment modalities by tumour stage could not be made.

The randomized as well as nonrandomized studies reported no difference in survival rates in patients treated either by enucleation or brachy-therapy when matched by the stage, age and other prognostic parameters.[@j_raon-2015-0009_ref_006]--[@j_raon-2015-0009_ref_008],[@j_raon-2015-0009_ref_0011],[@j_raon-2015-0009_ref_0012],[@j_raon-2015-0009_ref_0030]--[@j_raon-2015-0009_ref_0033] The largest of these studies was the COMS, which included 1317 patients and prospectively compared on randomized fashion enucleation and brachytherapy. There was no statistical difference in 5- and 10-year OS between the two treatment groups.[@j_raon-2015-0009_ref_0030] In the matched pairs study of Guthoff *et al.* melanoma specific survival at 12 years of follow-up was 77.9% in irradiated patients and 78.6% in enucleated patients (P \> 0.05).[@j_raon-2015-0009_ref_0031] When the OS at 10 years of our patients treated by brachytherapy was compared with that from COMS study, no difference could be observed: 32% vs. 35%; similarly, the DSS at 10 years in our series was 79% and was comparable with DSS reported by Guthoff.

There are several prognostic factors for outcome of the choroidal melanoma, including age[@j_raon-2015-0009_ref_0030]--[@j_raon-2015-0009_ref_0033], gender[@j_raon-2015-0009_ref_0033], basal tumour diameter[@j_raon-2015-0009_ref_0034], tumour thickness[@j_raon-2015-0009_ref_0033]--[@j_raon-2015-0009_ref_0037], T-stage[@j_raon-2015-0009_ref_0035], cell morphology[@j_raon-2015-0009_ref_001],[@j_raon-2015-0009_ref_007],[@j_raon-2015-0009_ref_0033],[@j_raon-2015-0009_ref_0038] and various genetic changes of the tumour, especially monosomy of chromosome 3.[@j_raon-2015-0009_ref_0033],[@j_raon-2015-0009_ref_0039]--[@j_raon-2015-0009_ref_0041] Some of them appeared statistically significant also in the present study, although the strength of our results should be interpreted with caution. Namely, we only had complete information on age and gender of the patients, histology of the enucleated tumours, and data of tumour diameter, thickness, irradiation dose on the base and top of the tumour and the treatment time for brachytherapy patients, but not also on some other highly relevant prognosticators (e.g. genetic alterations), which limits the strength of statistical analysis.

In both treatment groups, the post-treatment annual mortality related to melanoma at first increased, as expected due to systemic metastases, but few years later it decreased to a few or zero percent. In patients of 60 years or more who were treated by enucleation, mortality reached its peak of 18% at 3.7 years after treatment, while in patients younger than 60 years the peak was reached at six years after treatment and was 7%. Patients treated by brachytherapy fared better: regardless of age, six years after treatment completion the peak mortality was 3%. However, the mortality of irradiated patients aged ≥ 60 years reached the peak of 7% at 6 years post-treatment, while no increase in mortality was noticed among younger patients, probably due to the small number of deaths.

###### 

Univariate analysis of survival: patients treated by enucleation (N = 161)[^\*^](#j_raon-2015-0009_fn_004){ref-type="table-fn"}

                      DFS (%)   DSS (%)   OS (%)                                          
  -------------- ---- --------- --------- -------- ---- -------- ------- ------- -------- -------
                 n    5 yrs     10 yrs    p        5y   10 yrs   p       5 yrs   10 yrs   p
  Men            84   62        51        0.154    63   51               53      34       0.775
  Women          77   59        33        65       34   0,275    56      27               
  \< 60 years    82   73        52        0.001    76   52               74      51       0.000
  ≥ 60 years     79   49        30        50       30   0.000    34      10               
  Spindle cell   33   74        70                 81   72               66      49       
  epithelioid    38   56        36        0.050    61   33       0.029   55      24       0.026
  Mixed cell     23   62        28                 67   24               52      15       

None of enucleated patients had local recurrence; DFS = disease free survival; DSS = disease specific survival; n = number of patients; OS = overall survival; yrs = years

###### 

Multivariate analysis of survival of all patients (N = 288)

                                                               **HR**   **95% CI**   **P**     
  -------------- ----- --------------------------------------- -------- ------------ --------- -------
  All patients   LRC   First treatment                         40.842   5.565        299.717   0.000
                       Gender                                  2.658    1.245        5.678     0.012
                 DFS   First treatment                         1.628    1.144        2.316     0.007
                       Age \< 60 years vs. ≥ 60 years          1.800    1.275        2.540     0.001
                 DSS   First treatment                         3.937    2.509        6.178     0.000
                       Age \< 60 years vs. ≥ 60 years          2.534    1.714        3.747     0.000
                 OS    First treatment                         3.153    2.218        4.480     0.000
                       Age \< 60 years vs. ≥ 60 years          3.818    2.710        5.377     0.000
                       Gender                                  2.306    1.013        5.251     0.047
  Ruthenium      LRC                                                                           
                       Treatment time (≤ 96 h *vs.* \> 96 h)   2.841    1.220        6.623     0.015
                       Treatment time (≤ 96 h vs. \> 96 h)     2.674    1.276        5.587     0.009
                 DFS   Base (\< 11 mm *vs.* ≥ 11 mm)           2.519    1.015        6.250     0.046
                       T-stage                                 2.320    1.002        5.376     0.050
                 DSS   Age (\< 60 years *vs.* ≥ 60 years)      4.762    1.709        13.333    0.003
                 OS    Base (\< 11 mm *vs* v11 mm)             3.610    1.391        9.434     0.008
                       Age (\< 60 years *vs.* ≥ 60 years)      5.650    2.538        12.658    0.000
  Nucleation     LRC   \-                                      \-       \-           \-        \-
                 DFS   Age (\< 60 years *vs.* ≥ 60 years)      2.132    1.149        3.968     0.016
                       Histology S *VS* E VS M                 1.467    1.000        2.151     0.050
                 DSS   Age (\< 60 years *vs.* ≥ 60 years)      2.326    1.229        4.403     0.009
                       Histology S *vs.* E *vs.* M             1.555    1.052        2.298     0.027
                 OS    Age (\< 60 years vs. ≥ 60 years)        3.876    2.222        6.757     0.000
                       Histology (S *vs.* E *vs.* M)           1.444    1.051        1.983     0.023

CI = confident interval; DFS = disease free survival; DSS = disease specific survival; E = epitheloid; HR = hazard ratio; LRC = loco-regional control; M = mixed cell; n = number of patients; OS = overall survival; S = spindle cell

The increase in annual mortality following enucleation was first observed by Zimmermann.[@j_raon-2015-0009_ref_0042],[@j_raon-2015-0009_ref_0043] He re-analysed the data of Paul *et al.*[@j_raon-2015-0009_ref_0038] who monitored 2652 patients for 40 years and found a steep increase in mortality following enucleation. In this study, the peak of 8% was reached at 2 years after enucleation, slowly diminishing during the next few years to the "normal" 1%.[@j_raon-2015-0009_ref_0043],[@j_raon-2015-0009_ref_0044] Similarly, Seddon *et al.* reported the increase in mortality to 6.5 % in the first 2--3 years after treatment and slowly return to "normal" 1% during the next 7 years.[@j_raon-2015-0009_ref_0045]

The post-treatment increase in melanoma related mortality can be attributed to the loss of antiangiogenic activity of the primary tumour after its removal or destruction. Uveal melanoma cells produce angiostatin, growth inhibitor of metastatic foci[@j_raon-2015-0009_ref_0046],[@j_raon-2015-0009_ref_0047], which was found to be present in the circulation only up to five days after the removal of the primary tumour.[@j_raon-2015-0009_ref_0048],[@j_raon-2015-0009_ref_0049]

Damato *et al.*[@j_raon-2015-0009_ref_0033] found that the probability of metastases was greater in older patients as their tumours grew longer and had more time for accumulation of chromosome instabilities, making the tumour more malignant and more prone to metastasize. Accordingly, the younger patients should have smaller and perhaps less malignant tumours, and the appearance of metastases is less likely. It is assumed that following primary tumour removal, metastases in younger patients reach the lethal tumour mass at a later time. The peak in melanoma-related mortality in younger enucleated patients from our series appeared 2.5 years later than in older counterpart, confirming this assumption. However, not all patients from advanced age group have advanced primary tumour and metastases. In our series, 59 patients ≥ 60 years had primary tumours small enough to be treated by brachytherapy. The annual melanoma related mortality curve suggests that the burden of their metastases was also smaller, and reached the lethal mass at a later time. The synchronous peaks of enucleated patients \< 60 years and of irradiated patients ≥ 6o years suggests that the burden of metastases in enucleated group, was similar in these two groups ([Figure 3](#j_raon-2015-0009_fig_003){ref-type="fig"}).

There is no good scientific evidence that treatment can prolong patients' life.[@j_raon-2015-0009_ref_0033] The increase in annual post-treatment mortality rate implies that the life of some patients might be shortened due to the therapy, particularly of older ones. This observation and the fact that some tumours and their metastases grow very slowly raise the question when the treatment of uveal melanoma can be withheld. The COMS study showed that the estimated risk of death at 5 years of follow-up in 42 untreated patients was 50%, and risk of 1317 patients treated by a standard method, was 18%.[@j_raon-2015-0009_ref_0050] It seems that treatment in older patients without eyesight problems, in spite of evident metastases, could be postponed until the problems eventually ensue. On the other hand, it may be assumed that some of the younger patients are without micrometastases at the time of therapy and can be cured by the early treatment. Indeed, in our study, none of the patients younger than 40 years from brachytherapy group died of metastases, while death of metastases in older patients steeply increased with age ([Figure 4](#j_raon-2015-0009_fig_004){ref-type="fig"}).

To conclude, treatment-specific and age-dependent pattern of -related mortality was confirmed in our study, confirming observation of other authors. For quality of life reasons we believe that preference should be given to eyesight preserving brachytherapy or other eye preserving treatments of choroidal melanoma over enucleation, if the size and location are suitable even though the definite opinion on the best treatment differed in the literature.[@j_raon-2015-0009_ref_0051],[@j_raon-2015-0009_ref_0052]
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